|
US2011245288A1
|
|
Transdermally deliverable opioid prodrugs, abuse-resistant compositions and methods of using opioid prodrugs
|
|
US2011052694A1
|
|
Use of cannabidiol prodrugs in topical and transdermal administration with microneedles
|
|
EP2424525A1
|
|
Formulations of cannabidiol and methods of using the same
|
|
US2009246265A1
|
|
Abuse deterrent transdermal formulations of opiate agonists and agonist-antagonists
|
|
CA2705132A1
|
|
Prodrugs of tetrahydrocannabinol, compositions comprising prodrugs of tetrahydrocannabinol and methods of using the same
|
|
EP2478893A1
|
|
Methods and compositions for enhancing the viability of microneedle pores
|
|
WO2009018389A1
|
|
Prodrugs of cannabidiol, compositions comprising prodrugs of cannabidiol and methods of using the same
|
|
WO2008036980A1
|
|
Transdermally deliverable buprenorphine prodrugs and abuse-resistant compositions thereof
|
|
EP1895960A1
|
|
Transdermal delivery of cannabinoids
|
